Cardiff Oncology, Inc.

NasdaqCM:CRDF 주식 보고서

시가총액: US$149.2m

Cardiff Oncology 미래 성장

Future 기준 확인 0/6

Cardiff Oncology's revenue and earnings are forecast to decline at 32.6% and 29% per annum respectively while EPS is expected to decline by 19.8% per annum.

주요 정보

-29.0%

수익 성장률

-19.8%

EPS 성장률

Biotechs 수익 성장27.1%
매출 성장률-32.6%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트06 Sep 2024

최근 미래 성장 업데이트

Recent updates

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

수익 및 매출 성장 예측

NasdaqCM:CRDF - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20260-77-62-674
12/31/20250-57-49-485
12/31/20241-47-43-385
6/30/20241-41-32-32N/A
3/31/20241-40-31-30N/A
12/31/20230-41-31-31N/A
9/30/20230-41-34-33N/A
6/30/20230-40-33-33N/A
3/31/20230-39-33-32N/A
12/31/20220-39-35-34N/A
9/30/20220-39-33-32N/A
6/30/20220-38-30-30N/A
3/31/20220-34-28-27N/A
12/31/20210-28-23-23N/A
9/30/20210-25-21-21N/A
6/30/20210-23-19-19N/A
3/31/20210-24-19-19N/A
12/31/20200-23-17-16N/A
9/30/20200-20-15-14N/A
6/30/20200-20-14-14N/A
3/31/20200-17-13-13N/A
12/31/20190-17-13-13N/A
9/30/20190-17-14-14N/A
6/30/20190-16-14-14N/A
3/31/20190-19-14-14N/A
12/31/20180-19-13-13N/A
9/30/20180-18-13-13N/A
6/30/20181-18-16-16N/A
3/31/20181-20N/A-17N/A
12/31/20171-25N/A-23N/A
9/30/20170-31N/A-29N/A
6/30/20170-37N/A-29N/A
3/31/20170-39N/A-33N/A
12/31/20160-39N/A-31N/A
9/30/20160-38N/A-29N/A
6/30/20160-31N/A-27N/A
3/31/20160-31N/A-24N/A
12/31/20150-27N/A-22N/A
9/30/20150-25N/A-19N/A
6/30/20150-27N/A-17N/A
3/31/20150-18N/A-15N/A
12/31/20140-14N/A-13N/A
9/30/20140-11N/A-11N/A
6/30/20140-10N/A-9N/A
3/31/20140-14N/A-8N/A
12/31/20130-12N/A-7N/A

애널리스트 미래 성장 예측

수입 대 저축률: CRDF is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: CRDF is forecast to remain unprofitable over the next 3 years.

고성장 수익: CRDF is forecast to remain unprofitable over the next 3 years.

수익 대 시장: CRDF's revenue is expected to decline over the next 3 years (-32.6% per year).

고성장 수익: CRDF's revenue is forecast to decline over the next 3 years (-32.6% per year).


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if CRDF's Return on Equity is forecast to be high in 3 years time


성장 기업 발견